Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRNX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | — | 7.7 | 1.0 | 4.0 | 4.7 | 1.1 | 0.1 | 1.2 | 2.4 |
| Total Revenues | — | — | 1.0 | 4.0 | 4.7 | 1.1 | 0.1 | — | — |
| Cost of Revenues | — | 1.1 | — | 0.0 | — | — | — | — | — |
| Operating Expenses & Income | |||||||||
| Selling, General & Admin | — | 191.3 | — | 58.1 | — | — | — | — | — |
| R&D Expenses | 375.4 | 332.1 | 240.2 | 168.5 | 130.2 | 84.3 | 57.0 | 41.5 | 24.5 |
| Operating Income | (549.1) | (516.8) | (338.9) | (222.6) | (167.9) | (107.7) | (75.0) | (53.8) | (28.7) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | — | — | — | — | — | — | — | 0.0 |
| Interest & Investment Income | 48.4 | 52.0 | 41.4 | 13.4 | 4.3 | 0.2 | 1.0 | 3.5 | 1.7 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | (1.7) |
| Other Non-Operating Income / Expenses | 47.7 | 51.6 | 40.9 | 13.3 | 5.0 | 0.1 | 1.1 | 3.4 | 1.6 |
| EBT, Incl. Unusual Items | — | (465.1) | (298.4) | (209.3) | (163.9) | (107.6) | (73.8) | (50.4) | (27.1) |
| Income Tax Expense | — | 0.2 | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||
| Net Income | (501.6) | (465.3) | (298.4) | (214.5) | (163.9) | (107.6) | (73.8) | (50.4) | (27.1) |
| Per Share | |||||||||
| Basic EPS | (4.75) | (4.95) | (3.69) | (3.69) | (3.15) | (2.80) | (2.42) | — | — |
| Diluted EPS | (4.75) | (4.95) | (3.69) | (3.69) | (3.15) | (2.80) | (2.42) | — | — |
| Basic Weighted Avg Shares | 105.6 | 94.1 | 80.8 | 58.1 | 52.0 | 38.4 | 30.4 | — | — |
| Diluted Weighted Avg Shares | 105.6 | 94.1 | 80.8 | 58.1 | 52.0 | 38.4 | 30.4 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (512.9) | (336.1) | (221.5) | (166.9) | (106.8) | (74.0) | (52.9) | (28.2) |
| EBIT | (549.1) | (516.8) | (338.9) | (222.6) | (167.9) | (107.7) | (75.0) | (53.8) | (28.7) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.